Cellivery, US Patent Related to Pancreatic Cancer Treatment Candidate Substance
[Asia Economy Reporter Oh Ju-yeon] Cellivery announced on the 31st that it has acquired a U.S. patent related to the pancreatic cancer treatment candidate SOCS3 (Improved cell-permeable SOCS3: iCP-SOCS3), which activates the JAK/STAT signaling pathway. The company stated, "This allows us to negotiate from a favorable position during technology transfer discussions with global pharmaceutical companies."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Central Labor Relations Commission: "Second Post-Mediation Fails for Samsung Electronics"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Looks Even More Like Him in Person": Crowds Gather to See 'Trump Lookalike' Albino Buffalo
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
